Celcuity: From Speculative Bet To Pre-Commercial Powerhouse [Seeking Alpha]
Celcuity Inc. (CELC)
Last celcuity inc. earnings: 3/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
celcuity.com/home/investors
Company Research
Source: Seeking Alpha
Celcuity's gedatolisib demonstrated significant efficacy and a favorable safety profile in HR+/HER2- advanced breast cancer, supporting a strong investment thesis. With a completed NDA under the FDA's RTOR program and a $455M cash position, CELC is well-funded for commercialization and pipeline expansion. Risks have shifted from clinical to commercial execution, but CELC is positioned for long-term growth with pipeline opportunities beyond breast cancer. Tom Werner/DigitalVision via Getty Images In February, I covered Celcuity ( CELC ), stating that the stock price was fundamentally discounting its risk/reward ratio. By that time, Celcuity was a speculative play with deep skepticism around the toxicities associated with oral PI3K inhibitors This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article m
Show less
Read more
Impact Snapshot
Event Time:
CELC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELC alerts
High impacting Celcuity Inc. news events
Weekly update
A roundup of the hottest topics
CELC
News
- Celcuity (NASDAQ:CELC) had its price target raised by analysts at Jefferies Financial Group Inc. from $108.00 to $134.00. They now have a "buy" rating on the stock.MarketBeat
- Celcuity (CELC): Assessing Valuation Following Recent Share Price Surge [Yahoo! Finance]Yahoo! Finance
- This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results [Yahoo! Finance]Yahoo! Finance
- Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium [Yahoo! Finance]Yahoo! Finance
- Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer SymposiumGlobeNewswire
CELC
Earnings
- 11/12/25 - Beat
CELC
Sec Filings
- 12/5/25 - Form 144
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- CELC's page on the SEC website